523 related articles for article (PubMed ID: 29289556)
21. A sleeping giant: Suvorexant for the treatment of alcohol use disorder?
Campbell EJ; Marchant NJ; Lawrence AJ
Brain Res; 2020 Mar; 1731():145902. PubMed ID: 30081035
[TBL] [Abstract][Full Text] [Related]
22. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
[No Abstract] [Full Text] [Related]
23. Orexin receptor antagonists in the pathophysiology and treatment of sleep disorders and epilepsy.
Sheibani M; Shayan M; Khalilzadeh M; Ghasemi M; Dehpour AR
Neuropeptides; 2023 Jun; 99():102335. PubMed ID: 37003137
[TBL] [Abstract][Full Text] [Related]
24. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
Sun Y; Tisdale RK; Kilduff TS
Front Neurol Neurosci; 2021; 45():22-37. PubMed ID: 34052813
[TBL] [Abstract][Full Text] [Related]
25. Orexin OX
Jacobson LH; Chen S; Mir S; Hoyer D
Curr Top Behav Neurosci; 2017; 33():105-136. PubMed ID: 27909987
[TBL] [Abstract][Full Text] [Related]
26. Suvorexant: something new for sleep?
Reddy A; Puvvada SC; Kommisetti S; El-Mallakh RS; Lippmann S
Acta Neuropsychiatr; 2015 Feb; 27(1):53-5. PubMed ID: 25397996
[TBL] [Abstract][Full Text] [Related]
27. Promotion of Wakefulness and Energy Expenditure by Orexin-A in the Ventrolateral Preoptic Area.
Mavanji V; Perez-Leighton CE; Kotz CM; Billington CJ; Parthasarathy S; Sinton CM; Teske JA
Sleep; 2015 Sep; 38(9):1361-70. PubMed ID: 25845696
[TBL] [Abstract][Full Text] [Related]
28. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
Roecker AJ; Cox CD; Coleman PJ
J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
[TBL] [Abstract][Full Text] [Related]
29. The role of orexin in Alzheimer disease: From sleep-wake disturbance to therapeutic target.
Gao F; Liu T; Tuo M; Chi S
Neurosci Lett; 2021 Nov; 765():136247. PubMed ID: 34530113
[TBL] [Abstract][Full Text] [Related]
30. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.
Han Y; Yuan K; Zheng Y; Lu L
Neurosci Bull; 2020 Apr; 36(4):432-448. PubMed ID: 31782044
[TBL] [Abstract][Full Text] [Related]
31. Profile of suvorexant in the management of insomnia.
Sutton EL
Drug Des Devel Ther; 2015; 9():6035-42. PubMed ID: 26648692
[TBL] [Abstract][Full Text] [Related]
32. Suvorexant in the Treatment of Difficulty Falling and Staying Asleep (Insomnia).
Berger AA; Sottosanti ER; Winnick A; Keefe J; Gilbert E; Hasoon J; Thase ME; Kaye AD; Viswanath O; Urits I
Psychopharmacol Bull; 2022 Feb; 52(1):68-90. PubMed ID: 35342199
[TBL] [Abstract][Full Text] [Related]
33. Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease.
Kron JOJ; Keenan RJ; Hoyer D; Jacobson LH
Annu Rev Pharmacol Toxicol; 2024 Jan; 64():359-386. PubMed ID: 37708433
[TBL] [Abstract][Full Text] [Related]
34. Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia.
Yoshikawa F; Shigiyama F; Ando Y; Miyagi M; Uchino H; Hirose T; Kumashiro N
Diabetes Res Clin Pract; 2020 Nov; 169():108412. PubMed ID: 32911037
[TBL] [Abstract][Full Text] [Related]
35. Effect of Suvorexant vs Placebo on Total Daytime Sleep Hours in Shift Workers: A Randomized Clinical Trial.
Zeitzer JM; Joyce DS; McBean A; Quevedo YL; Hernandez B; Holty JE
JAMA Netw Open; 2020 Jun; 3(6):e206614. PubMed ID: 32484552
[TBL] [Abstract][Full Text] [Related]
36. Effects of an orexin receptor antagonist on blood pressure and metabolic parameters.
Moriyama S; Yanai H; Takeuchi Y; Hayakawa T
J Clin Hypertens (Greenwich); 2018 May; 20(5):978-980. PubMed ID: 29700927
[No Abstract] [Full Text] [Related]
37. Sleep disorders, obesity, and aging: the role of orexin.
Nixon JP; Mavanji V; Butterick TA; Billington CJ; Kotz CM; Teske JA
Ageing Res Rev; 2015 Mar; 20():63-73. PubMed ID: 25462194
[TBL] [Abstract][Full Text] [Related]
38. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice.
Kaushik MK; Aritake K; Cherasse Y; Imanishi A; Kanbayashi T; Urade Y; Yanagisawa M
Sleep; 2021 Aug; 44(8):. PubMed ID: 33609365
[TBL] [Abstract][Full Text] [Related]
39. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
De Boer P; Drevets WC; Rofael H; van der Ark P; Kent JM; Kezic I; Parapatics S; Dorffner G; van Gerven J; Beneš H; Keicher C; Jahn H; Seiden DJ; Luthringer R
J Psychopharmacol; 2018 Jun; 32(6):668-677. PubMed ID: 29848147
[TBL] [Abstract][Full Text] [Related]
40. Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders.
Pałasz A; Lapray D; Peyron C; Rojczyk-Gołębiewska E; Skowronek R; Markowski G; Czajkowska B; Krzystanek M; Wiaderkiewicz R
Int J Neuropsychopharmacol; 2014 Jan; 17(1):157-68. PubMed ID: 23702225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
